To appeal Mavyret coverage, individuals typically need to understand the reason for denial and gather supporting documentation. Insurance companies deny coverage for various reasons, including lack of medical necessity, experimental use, or if the drug is not on their formulary [1].
Why Was Mavyret Coverage Denied?
Coverage for Mavyret can be denied if it's determined not to be medically necessary for the patient's specific condition, if the insurer believes a less expensive alternative is available, or if Mavyret is not listed on the health plan's list of covered drugs (formulary) [1].
What Information is Needed for an Appeal?
Appeals generally require a letter of medical necessity from the prescribing physician, detailing why Mavyret is the most appropriate treatment. This may include information about the patient's specific genotype of hepatitis C, previous treatment failures, and any contraindications to alternative therapies [1]. Documentation of the denial itself, such as the Explanation of Benefits (EOB), is also crucial.
How to Submit an Appeal for Mavyret
The appeal process usually begins with an internal appeal to the insurance company. This involves submitting the necessary documentation within a specified timeframe, often 180 days from the denial date [1]. If the internal appeal is unsuccessful, a further external review by an independent third party may be possible [1].
Can Mavyret Be Prescribed Off-Label for Coverage Appeals?
Mavyret is FDA-approved for the treatment of chronic hepatitis C virus (HCV) infection in adults across all major genotypes [2]. If a physician prescribes Mavyret for a condition or patient population not explicitly listed in the FDA-approved labeling (off-label use), coverage denials are more likely. Appeals for off-label use require robust scientific and clinical evidence to demonstrate the treatment's efficacy and safety in that specific context [1].
What Are Alternatives to Mavyret?
Several other direct-acting antiviral (DAA) medications are available for treating hepatitis C, some of which may be preferred or covered differently by insurance plans. These include treatments like Epclusa, Harvoni, and Zepatier, among others [3]. The choice of treatment often depends on the specific HCV genotype, liver disease severity, and individual patient factors [3].
When Did Mavyret's Patent Expire?
Information regarding Mavyret's patent expiry is available through specialized resources. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Mavyret [4].
---
Sources
1. https://www.drugpatentwatch.com/
2. AbbVie. Mavyret (glecaprevir and pibrentasvir) Tablets. Prescribing Information. 2023.
3. https://www.hcvguidelines.org/
4. https://www.drugpatentwatch.com/